Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

N/AActive Not RecruitingNCT03957252

Nanostics2,800 enrolled

Overview

This ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy due to suspicion of prostate cancer. The study will compare ClarityDX Prostate test results with biopsy outcomes to determine the test's ability to identify the presence of clinically significant prostate cancer.

The main objective of this study is to validate ClarityDX Prostate as a reflex test to PSA to refine the prediction of clinically-significant prostate cancer in a prospective cohort of men to be recruited in North America when they are scheduled for a biopsy as a result of on an elevated PSA or other suspicion of prostate cancer and in retrospective databases from selected sites in the United States of America and the world. The training and validation analysis sets will consist of up to 2,800 consenting men from Alberta in addition to up to 5,000 men from external institutions, between ages 40-75 (inclusive) years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer.

Study Type

OBSERVATIONAL

Enrollment

2,800

Conditions

Prostate Cancer Prostate Cancer Screening Performance Assessment of Novel Test

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: 1. Males between 40-75 (inclusive) years of age; 2. With and without family history of prostate cancer; 3. No prior prostate cancer diagnosis and who are referred to have a prostate biopsy; 4. Total PSA results \>/= 3ng/mL collected within 6m of enrollment; 5. Willing to permit provincial agencies (e.g. Alberta Health Services, Alberta Health, Netcare, Service Alberta or other based on recruitment jurisdiction) to disclose health-related information to study; 6. Undergoing a diagnostic prostate biopsy; and 7. Provided informed consent to participate in the study. Exclusion Criteria: 1. Unwilling to participate in the study; 2. Unavailable for biopsy procedure in recruitment areas; 3. Not undergoing a prostate biopsy; 4. Prior diagnosis of cancer excluding non-melanoma skin cancer; and/or 5. Under the age of 40 years of age or over the age of 75 years of age.

Locations (3)

Johns Hopkins University

Baltimore, Maryland, United States

Prostate Cancer Centre

Calgary, Alberta, Canada

Kipnes Urology Centre

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

Diagnostic Clinical Performance: prediction of clinically significant prostate cancer at biopsy

Training Phase: Processed clinical features of each patient will be analyzed using machine learning to predict clinically significant prostate cancer, with the output being the ClarityDX Prostate Risk Score. Validation Phase: The models created during the Training Phase will be locked down and then used to determine the probability of approximately 1,400 patients in the investigational Validation Phase having clinically significant prostate cancer.

Time frame: 3 years

Active Surveillance: prediction of Gleason Grade Group on confirmatory/follow-up biopsies for participants on Active Surveillance

Time frame: 4 years

MRI: prediction of PI-RADS pre-diagnostic biopsy

Time frame: 4 years

Secondary Outcomes

Health economics

Perform health economics and cost-benefit analyss of the test

Time frame: 3 years

Medication and co-morbidities

Effect of selected medications and co-morbidities on the predictive value of the test

Time frame: Baseline

Analytical validity of the ClarityDX Prostate test

Method assessment and analytical validity of the ClarityDX Prostate test.

Time frame: 1 year post enrollment